Funding Announcement: MBX Biosciences Raises $63.5 Million in Series C Round to Advance Pioneering Precision Endocrine Peptides for Endocrine Disorders

MBX Biosciences, Inc. is excited to announce a significant funding milestone, having successfully raised $63.5 million in its latest financing round. As a clinical stage biopharmaceutical company, MBX is at the forefront of developing investigational Precision Endocrine Peptides (PEPs™), a novel class of therapeutics designed to address the limitations traditionally associated with native peptide treatments. The funds raised will be instrumental in advancing MBX’s pipeline of PEP candidates, particularly its lead product, MBX 2109, which is currently undergoing a Phase 1 clinical trial for the treatment of hypoparathyroidism. This groundbreaking therapy aims to meet the pressing needs of patients suffering from endocrine disorders, where existing treatments often fall short. The company is backed by esteemed life science investors such as Frazier Life Sciences, New Enterprise Associates, and OrbiMed, who recognize the potential of MBX’s innovative approach. With a leadership team that brings decades of collective expertise in the discovery, development, and commercialization of successful endocrine therapies—including notable products like Forteo® and Humalog®—MBX Biosciences is poised to make a meaningful impact on the field of endocrine treatment. The current funding will not only accelerate the development of their PEP candidates but also ensure that MBX remains dedicated to offering new solutions for patients with unmet medical needs. As MBX continues its journey, the company remains focused on transforming the landscape of endocrine therapeutics and improving the lives of those affected by these challenging conditions.